Efficacy of single-dose galcanezumab 240 mg on episodic or refractory chronic cluster headache: prospective, 4-week, real-world evidence from the GRASP study group
- DOI
- 10.3389/fneur.2025.1748498
- Published
- 2026-01-12
- Container
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fneur.2025.1748498,
title = {Efficacy of single-dose galcanezumab 240 mg on episodic or refractory chronic cluster headache: prospective, 4-week, real-world evidence from the GRASP study group},
author = {Michail Vikelis and Andreas A. Argyriou and Maria Chondrogianni and Aikaterini Foska and Dimitrios Rikos and Christos Tsironis and Panagiotis Soldatos and Maria Koutsokera and Emmanouil V. Dermitzakis},
year = {2026},
journal = {Frontiers in Neurology},
doi = {10.3389/fneur.2025.1748498},
url = {https://doi.org/10.3389/fneur.2025.1748498}
}RIS
TY - JOUR TI - Efficacy of single-dose galcanezumab 240 mg on episodic or refractory chronic cluster headache: prospective, 4-week, real-world evidence from the GRASP study group AU - Michail Vikelis AU - Andreas A. Argyriou AU - Maria Chondrogianni AU - Aikaterini Foska AU - Dimitrios Rikos AU - Christos Tsironis AU - Panagiotis Soldatos AU - Maria Koutsokera AU - Emmanouil V. Dermitzakis PY - 2026 JO - Frontiers in Neurology DO - 10.3389/fneur.2025.1748498 UR - https://doi.org/10.3389/fneur.2025.1748498 ER -
APA
Vikelis, M., Argyriou, A. A., Chondrogianni, M., Foska, A., Rikos, D., Tsironis, C., Soldatos, P., Koutsokera, M., & Dermitzakis, E. V. (2026). Efficacy of single-dose galcanezumab 240 mg on episodic or refractory chronic cluster headache: prospective, 4-week, real-world evidence from the GRASP study group. Frontiers in Neurology. https://doi.org/10.3389/fneur.2025.1748498
Source records
- crossref · retrieved 2026-11-10T14:01:27.113Z